• argenx launched a cash tender offer for all outstanding Forte Biosciences shares at USD 77 per share.
• Offer follows a July 26, 2026 merger agreement between the companies.
• Tender offer set to expire Aug. 26, 2026 at 11:59 p.m. ET, unless extended or terminated earlier.
• Closing conditions include majority of shares tendered, measured as more than 50% of shares outstanding.
• Deal not subject to a financing condition; a second-step merger would make Forte a wholly owned argenx unit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.